News

Step Pharma Advances Cancer Treatment Strategies Through Research

Step Pharma Advances Cancer Treatment Strategies Through Research

Step Pharma Advances Cancer Treatment Strategies Through Research

Step Pharma, a pioneering company in targeted cancer therapies, is preparing to showcase groundbreaking research on CTPS2-null solid tumors at an esteemed international conference. As the global leader in CTPS1 inhibition, Step Pharma's innovative approach aims to revolutionize cancer treatment methodologies and improve patient outcomes.

Exciting Conference Presentation on Synthetic Lethality

At the upcoming EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, the Chief Scientific Officer, Philip Beer, will present key findings related to synthetic lethality in solid tumors. This research is particularly focused on utilizing AACR Project GENIE data, a critical resource of clinico-genomic information, to identify loss of CTPS2 as a pivotal biomarker. This discovery holds immense potential for selecting specific solid tumors that rely on CTPS1 for survival.

Understanding the Significance of CTPS2

The loss of CTPS2 is a frequent occurrence across various cancer types, especially prevalent in ovarian cancer. This finding is transformative since tumors arising from epithelial tissues are capable of using CTPS1 and CTPS2 in their metabolic pathways. The absence of CTPS2 creates a vulnerability that can be targeted through CTPS1 inhibition, ultimately aiming to halt tumor proliferation.

Precision Oncology Approach with Dencatistat

In light of these insightful findings, Step Pharma is positioning dencatistat, a potent oral CTPS1 inhibitor, at the forefront of their clinical exploration. This compound is currently being assessed in a phase 1a dose escalation study for patients with solid tumors. Notably, there will be safety expansion cohorts specifically for patients with CTPS2-null tumors, beginning with ovarian cancer.

Maximizing Therapeutic Potential

Targeting patients whose tumors have lost CTPS2 exemplifies a precise oncology strategy that optimizes the therapeutic application of dencatistat. This choice aligns with contemporary approaches in personalized medicine, ensuring patients receive treatments tailored to their specific tumor characteristics.

The Role of Advanced Data in Cancer Research

Philip Beer emphasized the significance of analyzing clinico-genomic data, stating, "Our efforts to investigate this data led us to identify promising therapeutic avenues for patients with CTPS2-null solid tumors. With the deletion found in approximately 15-20% of ovarian cancer cases, we are excited about the potential to selectively target cancerous cells through the inhibition of CTPS1. This targeted strategy is a critical advancement in our journey to revolutionize cancer treatment."

About Step Pharma

Founded in 2014, Step Pharma aims to transform the landscape of cancer treatment through innovative targeted therapies that effectively eradicate cancer cells while sparing healthy cells. The company specializes in CTPS1 inhibition, offering the prospect of highly selective, safe, and effective treatments for both hemato-oncological and solid tumors.

Step Pharma, headquartered in Saint-Genis-Pouilly, has garnered support from a robust consortium of investors such as Kurma Partners and V-Bio Ventures. Their mission is supported by the remarkable scientific contributions of renowned figures like Prof. Alain Fischer and Dr. Sylvain Latour. For further information about Step Pharma's innovative work in oncology, visit www.step-ph.com.

Frequently Asked Questions

What is the focus of Step Pharma's upcoming presentation?

Step Pharma will focus on its research concerning CTPS2-null solid tumors and the potential of using dencatistat in treating these cancers.

What role does CTPS2 play in cancer treatment?

CTPS2 is identified as a novel biomarker for certain solid tumors, indicating dependence on CTPS1, which can be targeted for effective treatment.

What is dencatistat?

Dencatistat is an orally available, highly potent inhibitor of CTPS1 currently being studied for its effectiveness against solid tumors.

What percentage of ovarian cancers are associated with CTPS2 deletion?

Approximately 15-20% of ovarian cancers feature the deletion of CTPS2, making it a significant target for precision oncology.

Who is the current Chief Executive Officer of Step Pharma?

The Chief Executive Officer of Step Pharma is Andrew Parker, who leads the company's strategic directions and research initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 45

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 53

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 24

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 35

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Renesas Electronics Reveals Optimistic Financial Expectations

Updated Category News Views 68

Renesas Electronics Unveils Future Financial Outlook Renesas Electronics Corporation (TSE: 6723), a leading name in the semiconductor industry, has recently shared its consolidated financial forecasts for the complete fiscal year. This announcement highlights the Group's optimistic projections for the year ending December 31, 2024, despite the inherent volatility seen in...

Continue Reading
Atos Achieves European Leadership in Mainframe Solutions Ranking

Updated Category News Views 213

Atos Secures Top Position in ISG’s Mainframes Evaluation Atos has proudly announced its recognition as a leader in ISG’s Provider Lens™ Mainframes – Services and Solutions for the fourth consecutive year. This accolade highlights Atos' extensive experience, innovative strategies, and commitment to excellence in service delivery. Leadership in Multiple Quadrants In...

Continue Reading
Custom Upholstered Furniture: Comfort Built to Last

Updated Category News Views 150

Rethinking Furniture Comfort: Not Just a Luxury Diving into the world of custom upholstered furniture with insights from Randy Marohn is like finding a cheat sheet for comfort. Seriously, it ain't just about plush cushions or slick fabrics—it's a bonafide science. Marohn, from Sans Furniture Inc. in good ol’ Hamburg, NY, unfolds a tale of intentional design and...

Continue Reading
Cyble Achieves Users' Love Badge With Outstanding Category Wins

Updated Category News Views 84

Cyble Earns G2 'Users Love Us' Badge for Winter 2026 Cyble, a leader in the field of AI-driven cybersecurity and threat intelligence, has recently achieved significant recognition in the G2 Winter 2026 Reports. This includes acquiring the esteemed 'Users Love Us' badge, along with 18 category victories within the domains of threat intelligence, digital risk protection,...

Continue Reading
SunPower Strengthens Sales Force for Future Expansion

Updated Category News Views 210

SunPower Expands Its Sales Force to Drive Future Growth Recently, SunPower Inc. (NASDAQ: SPWR) has made significant strides in expanding its sales force after successfully integrating the sales team from Sunder Energy. The merger promises to boost SunPower's operational effectiveness while setting the stage for unprecedented revenue potential. The company is poised to...

Continue Reading